← Back to all trials
Recruiting
NCT06883305
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Sex: All
Ages: 40 Years – 80 Years
Healthy volunteers: No
Phase: PHASE3
Enrollment: 990
Sponsor: AstraZeneca
Location: Research Site Foley Alabama
Summary
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
Eligibility Criteria
Inclusion Criteria:
1. ≥40 to ≤80 years old
2. COPD diagnosis ≥1 year,
3. Post-BD FEV1 ≥ 20% and ≤ 70% PN, FEV1/FVC \4.0 L/min or O2 saturation \
Source: ClinicalTrials.gov (NCT06883305). StuddyBuddy aggregates publicly available trial information.
